Sanofi, a prominent pharmaceutical company in Europe, has a diverse sales structure. Pharmaceutical products make up 70.6% of their total sales. Within this category, specialty medicines are the dominant segment, accounting for 59.3% of sales. These medicines focus on treating various conditions such as multiple sclerosis, neurological and inflammatory diseases, autoimmune disorders, rare diseases, cancers, and rare hematological conditions.

General medicine contributes 40.7% of sales, with a primary focus on diabetes and cardiovascular diseases. Human vaccines represent 17.4% of sales and include pediatric vaccines, flu, meningitis, and polio vaccines, as well as booster shots and vaccines for travelers. Consumer healthcare products make up the remaining 12% of sales.

Sanofi plans to have 54 production sites globally by the end of 2023, highlighting their extensive manufacturing capabilities. Geographically, their sales are distributed as follows: France accounts for 5.5%, Europe 18.6%, the United States 43%, North America 1.6%, and other regions 31.3%. This demonstrates Sanofi's significant presence in the global healthcare industry.